244 related articles for article (PubMed ID: 15816481)
21. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
22. The impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudine.
Gotto J; Webster GJ; Brown D; Jenkins J; Dusheiko GM; Bertoletti A
J Viral Hepat; 2006 Jun; 13(6):415-25. PubMed ID: 16842445
[TBL] [Abstract][Full Text] [Related]
23. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.
Chang ML; Chien RN; Yeh CT; Liaw YF
J Hepatol; 2005 Jul; 43(1):72-7. PubMed ID: 15896869
[TBL] [Abstract][Full Text] [Related]
24. [Predictive factors and clinical outcome of viral breakthrough during lamivudine treatment for chronic hepatitis B infection].
Park NH; Shin JW; Park JH; Bang SJ; Kim DH; Joo KR; Kim DH
Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):293-303. PubMed ID: 14695696
[TBL] [Abstract][Full Text] [Related]
25. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
[TBL] [Abstract][Full Text] [Related]
26. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
[TBL] [Abstract][Full Text] [Related]
27. [Relation of serological markers of hepatitis B virus and alanine transaminase to hepatic tissue pathology in patients with chronic hepatitis B].
Yang XY; Wen FY; Wu JL; Zhou HJ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):892-3. PubMed ID: 16793626
[TBL] [Abstract][Full Text] [Related]
28. A preliminary trial of lamivudine for chronic hepatitis B infection.
Dienstag JL; Perrillo RP; Schiff ER; Bartholomew M; Vicary C; Rubin M
N Engl J Med; 1995 Dec; 333(25):1657-61. PubMed ID: 7477217
[TBL] [Abstract][Full Text] [Related]
29. Histological outcome during long-term lamivudine therapy.
Dienstag JL; Goldin RD; Heathcote EJ; Hann HW; Woessner M; Stephenson SL; Gardner S; Gray DF; Schiff ER
Gastroenterology; 2003 Jan; 124(1):105-17. PubMed ID: 12512035
[TBL] [Abstract][Full Text] [Related]
30. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.
Lo CM; Liu CL; Chan SC; Lau GK; Fan ST
J Hepatol; 2005 Aug; 43(2):283-7. PubMed ID: 15964658
[TBL] [Abstract][Full Text] [Related]
31. Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
Chen JY; Wang LW; Sun XM; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):393-7. PubMed ID: 16109523
[TBL] [Abstract][Full Text] [Related]
32. [A study on the clinical and pathological efficacy of lamivudine in the treatment of chronic hepatitis B].
Yang C; Xiao YH; Guan XQ; Yuan Z
Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):364-7. PubMed ID: 15225436
[TBL] [Abstract][Full Text] [Related]
33. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
[TBL] [Abstract][Full Text] [Related]
34. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance.
Hsu CW; Yeh CT; Chang ML; Liaw YF
Gastroenterology; 2007 Feb; 132(2):543-50. PubMed ID: 17258721
[TBL] [Abstract][Full Text] [Related]
35. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.
Perrillo R; Rakela J; Dienstag J; Levy G; Martin P; Wright T; Caldwell S; Schiff E; Gish R; Villeneuve JP; Farr G; Anschuetz G; Crowther L; Brown N
Hepatology; 1999 May; 29(5):1581-6. PubMed ID: 10216146
[TBL] [Abstract][Full Text] [Related]
36. Response of pre-core mutant chronic hepatitis B infection to lamivudine.
Rizzetto M; Volpes R; Smedile A
J Med Virol; 2000 Jul; 61(3):398-402. PubMed ID: 10861653
[TBL] [Abstract][Full Text] [Related]
37. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Zhu M; Xu B; Yao GB
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
[TBL] [Abstract][Full Text] [Related]
38. [One year treatment with lamivudine in different hepatitis B virus related hepatic diseases].
Buti M; Cotrina M; Cruz de Castro E; Jardí R; Rodríguez F; Esteban R; Guardia J
Gastroenterol Hepatol; 1999 Mar; 22(3):117-21. PubMed ID: 10228320
[TBL] [Abstract][Full Text] [Related]
39. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy.
Bourne EJ; Dienstag JL; Lopez VA; Sander TJ; Longlet JM; Hall JG; Kwiatkowski RW; Wright T; Lai CL; Condreay LD
J Viral Hepat; 2007 Jan; 14(1):55-63. PubMed ID: 17212645
[TBL] [Abstract][Full Text] [Related]
40. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
